Alain H Litwin1, John Jost2, Katherine Wagner3, Moonseong Heo4, Alison Karasz5, Judith Feinberg6, Arthur Y Kim7, Paula J Lum8, Shruti H Mehta9, Lynn E Taylor10, Judith I Tsui11, Irene Pericot-Valverde12, Kimberly Page3. 1. Clemson University School of Health Research, Clemson, SC, USA; Department of Medicine, University of South Carolina School of Medicine, Greenville, SC, USA; Department of Medicine, Prisma Health, Greenville, SC, USA. Electronic address: Alain.Litwin@prismahealth.org. 2. Department of Medicine, Montefiore Medical Center, Bronx, NY, USA. 3. Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA. 4. Department of Public Health Sciences, College of Behavioral, Social, and Health Sciences, Clemson University Clemson, SC, USA. 5. Einstein College of Medicine, Bronx, NY, USA. 6. Department of Behavioral Medicine & Psychiatry and Department of Medicine, West Virginia University, Morgantown, WV, USA. 7. Department of Infectious Diseases, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. 8. Department of Medicine, University of California San Francisco, San Francisco, CA, USA. 9. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 10. College of Pharmacy, University of Rhode Island, CODAC Behavioral Health, Providence, RI, USA. 11. Department of Medicine, University of Washington, Seattle, WA, USA. 12. Clemson University School of Health Research, Clemson, SC, USA; Department of Medicine, Prisma Health, Greenville, SC, USA.
Abstract
BACKGROUND: Although people who inject drugs (PWID) having the highest incidence and prevalence of hepatitis C virus (HCV) in the US, HCV treatment is rarely provided to PWID due to assumptions about poor adherence and reinfection risk. As direct-acting antiviral agents (DAAs) have achieved sustained virologic response (SVR) rates of 95% or more, evidence-based strategies are urgently needed to demonstrate real-world effectiveness in marginalized patient populations such as PWID. The objectives of this study are: 1) to determine whether either of two patient-centered treatment models - patient navigation (PN) or modified directly observed therapy (mDOT) - results in more forward movement along the HCV care cascade including treatment initiation, adherence, and SVR; 2) using quantitative and qualitative methods, to understand factors associated with lack of treatment uptake, poor adherence (<80%), failure to achieve SVR, DAA resistance, and HCV reinfection. METHODS: The HERO study is a multi-site, pragmatic randomized clinical trial conducted in eight states where 754 HCV-infected PWID were randomly assigned to either PN or mDOT. CONCLUSIONS: This study addresses an urgent need for timely and accurate information on optimal models of care to promote HCV treatment initiation, adherence, treatment completion and SVR among PWID, as well as rates and factors associated with reinfection and resistance after treatment. This clinical trial has the potential to provide valuable information on how to reduce the burden of the HCV epidemic in PWID. Published by Elsevier Inc.
RCT Entities:
BACKGROUND: Although people who inject drugs (PWID) having the highest incidence and prevalence of hepatitis C virus (HCV) in the US, HCV treatment is rarely provided to PWID due to assumptions about poor adherence and reinfection risk. As direct-acting antiviral agents (DAAs) have achieved sustained virologic response (SVR) rates of 95% or more, evidence-based strategies are urgently needed to demonstrate real-world effectiveness in marginalized patient populations such as PWID. The objectives of this study are: 1) to determine whether either of two patient-centered treatment models - patient navigation (PN) or modified directly observed therapy (mDOT) - results in more forward movement along the HCV care cascade including treatment initiation, adherence, and SVR; 2) using quantitative and qualitative methods, to understand factors associated with lack of treatment uptake, poor adherence (<80%), failure to achieve SVR, DAA resistance, and HCV reinfection. METHODS: The HERO study is a multi-site, pragmatic randomized clinical trial conducted in eight states where 754 HCV-infected PWID were randomly assigned to either PN or mDOT. CONCLUSIONS: This study addresses an urgent need for timely and accurate information on optimal models of care to promote HCV treatment initiation, adherence, treatment completion and SVR among PWID, as well as rates and factors associated with reinfection and resistance after treatment. This clinical trial has the potential to provide valuable information on how to reduce the burden of the HCV epidemic in PWID. Published by Elsevier Inc.
Authors: Shruti H Mehta; Gregory M Lucas; Lisa B Mirel; Michael Torbenson; Yvonne Higgins; Richard D Moore; David L Thomas; Mark S Sulkowski Journal: AIDS Date: 2006-11-28 Impact factor: 4.177
Authors: Paul K Nelson; Bradley M Mathers; Benjamin Cowie; Holly Hagan; Don Des Jarlais; Danielle Horyniak; Louisa Degenhardt Journal: Lancet Date: 2011-07-27 Impact factor: 79.321
Authors: William O Osburn; Brian E Fisher; Kimberly A Dowd; Giselle Urban; Lin Liu; Stuart C Ray; David L Thomas; Andrea L Cox Journal: Gastroenterology Date: 2009-09-24 Impact factor: 22.682
Authors: Christoph Sarrazin; Vasily Isakov; Evguenia S Svarovskaia; Charlotte Hedskog; Ross Martin; Krishna Chodavarapu; Diana M Brainard; Michael D Miller; Hongmei Mo; Jean-Michel Molina; Mark S Sulkowski Journal: Clin Infect Dis Date: 2016-10-12 Impact factor: 9.079
Authors: Natasha K Martin; Peter Vickerman; Jason Grebely; Margaret Hellard; Sharon J Hutchinson; Viviane D Lima; Graham R Foster; John F Dillon; David J Goldberg; Gregory J Dore; Matthew Hickman Journal: Hepatology Date: 2013-08-26 Impact factor: 17.425
Authors: Donna M Evon; Christopher B Hurt; Delesha M Carpenter; Sarah K Rhea; Caitlin M Hennessy; William A Zule Journal: Rural Ment Health Date: 2022-02-03
Authors: Adam Baus; Andrea Calkins; Judith Feinberg; Kim McManaway; Susan Moser; Cecil Pollard; Richard Sutphin Journal: Perspect Health Inf Manag Date: 2022-01-01
Authors: Irene Pericot-Valverde; Moonseong Heo; Jiajing Niu; Brianna L Norton; Matthew J Akiyama; Linda Agyemang; Alain H Litwin Journal: Open Forum Infect Dis Date: 2020-10-10 Impact factor: 3.835
Authors: Aliza Monroe-Wise; Loice Mbogo; Brandon Guthrie; David Bukusi; Betsy Sambai; Bhavna Chohan; John Scott; Peter Cherutich; Helgar Musyoki; Rose Bosire; Matthew Dunbar; Paul Macharia; Sarah Masyuko; Eduan Wilkinson; Tulio De Oliveira; Natasha Ludwig-Barron; Bill Sinkele; Joshua Herbeck; Carey Farquhar Journal: BMJ Open Date: 2021-04-24 Impact factor: 2.692
Authors: Eric Tatara; Alexander Gutfraind; Nicholson T Collier; Desarae Echevarria; Scott J Cotler; Marian E Major; Jonathan Ozik; Harel Dahari; Basmattee Boodram Journal: PLoS One Date: 2022-03-10 Impact factor: 3.240